GLP-1 agonist exposure around conception: no clear harm signal, not proof of safety

Design

Systematic review and random-effects meta-analysis of 10 observational studies

Population

2,118,215 pregnancies; 8,325 exposed to GLP-1 receptor agonists within 6 months before a positive test

Primary outcome

Miscarriage, congenital anomalies, preterm birth and other maternal and perinatal outcomes

Effect

No clear increase in any outcome; pre-eclampsia OR 0.87 (95% CI 0.78–0.98) from two datasets

A systematic review pooled ten observational studies of more than two million pregnancies, 8,325 of them exposed to a GLP-1 receptor agonist in the six months before a positive pregnancy test. Outcomes ran from miscarriage and malformations to preterm birth, hypertensive disorders, gestational diabetes and fetal growth.

None of the pooled estimates showed a clearly detectable rise in harm. Pre-eclampsia was slightly lower in exposed pregnancies (OR 0.87, 95% CI 0.78–0.98), but that rests on only two datasets. Results did not differ by whether the drug was prescribed for diabetes or for weight.

The authors are explicit that this does not establish safety: the studies were heterogeneous, confounding cannot be removed, and the malformation analysis drew on just four studies. Its use is in the clinic after an unplanned pregnancy, where it supports calm counselling rather than alarm. Labels still advise stopping these drugs before a planned pregnancy, and that has not changed.

• Ask about pregnancy plans and contraception when starting a GLP-1 agonist in a woman of reproductive age.
• Plan to stop the drug before a planned conception, in line with current labelling.
• After an unplanned exposure, stop the drug and counsel that pooled data show no clear rise in malformations or miscarriage.
• Expect more unplanned exposures as weight loss improves fertility in women with obesity or polycystic ovary syndrome.

Why it matters

Weight loss on these drugs restores ovulation, so unplanned exposure is becoming a routine consultation.

Don't overread it

These were observational studies; they cannot show the drugs are safe in pregnancy or that they prevent pre-eclampsia.

The statistics, in plain English

An odds ratio of 0.87 for pre-eclampsia means about 13% lower odds, and the interval of 0.78 to 0.98 just excludes no difference. But two datasets cannot carry that claim, and absence of a signal in observational data is not the same as evidence of no risk.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.